Novo's pioneering diabetes pill beats Victoza, Januvia in tests

COPENHAGEN (Reuters) - Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co's Januvia and its own best-selling injectable treatment Victoza in tests.